The latest price target for PMV Pharma (NASDAQ:PMVP) was reported by HC Wainwright & Co. on August 20, 2024. The analyst firm set a price target for $5.00 expecting PMVP to rise to within 12 months (a possible 216.46% upside). 8 analyst firms have reported ratings in the last year.

The latest analyst rating for PMV Pharma (NASDAQ:PMVP) was provided by HC Wainwright & Co., and PMV Pharma reiterated their buy rating.

The last upgrade for PMV Pharmaceuticals Inc happened on March 2, 2022 when Oppenheimer raised their price target to N/A. Oppenheimer previously had a perform for PMV Pharmaceuticals Inc.

There is no last downgrade for PMV Pharma.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of PMV Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for PMV Pharma was filed on August 20, 2024 so you should expect the next rating to be made available sometime around August 20, 2025.

While ratings are subjective and will change, the latest PMV Pharma (PMVP) rating was a reiterated with a price target of $5.00 to $5.00. The current price PMV Pharma (PMVP) is trading at is $1.58, which is out of the analyst’s predicted range.